Transition metal based anticancer drugs

Curr Top Med Chem. 2011;11(5):521-42. doi: 10.2174/156802611794785226.

Abstract

With an ageing baby-boomer population in the Western World, cancer is becoming a significant cause of death. The prevalence of cancer and all associated costs, both in human and financial terms, drives the search for new therapeutic drugs and treatments. Platinum anticancer agents, such as cisplatin have been highly successful but there are several disadvantages associated with their use. What is need are new compounds with different mechanisms of action and resistance profiles. What needs to be recognised is that there are many other metal in the periodic table with therapeutic potential. Here we have highlighted metal complexes with activity and have illustrate the different approaches to the design of anticancer complexes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • DNA, Neoplasm / chemical synthesis
  • DNA, Neoplasm / chemistry
  • DNA, Neoplasm / drug effects
  • Drug Screening Assays, Antitumor
  • Humans
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Organometallic Compounds / chemistry
  • Organometallic Compounds / pharmacology*
  • Transition Elements / chemistry*

Substances

  • Antineoplastic Agents
  • DNA, Neoplasm
  • Organometallic Compounds
  • Transition Elements